These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35023374)

  • 21. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol use and HIV pharmacotherapy.
    Bean P
    Am Clin Lab; 2000 Jun; 19(5):16. PubMed ID: 11010310
    [No Abstract]   [Full Text] [Related]  

  • 23. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.
    Chang WC; Tanoshima R; Ross CJD; Carleton BC
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():65-84. PubMed ID: 33006916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of HIV therapy.
    Owen A; Pirmohamed M; Khoo SH; Back DJ
    Pharmacogenet Genomics; 2006 Oct; 16(10):693-703. PubMed ID: 17001288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV/AIDS treatment.
    Zakeri S; Amiri N; Pirahmadi S; Dinparast Djadid N
    Arch Iran Med; 2014 Oct; 17(10):685-91. PubMed ID: 25305768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients.
    Vidal F; Leal M; Alcamí J; Domingo P
    Pharmacogenomics; 2014 Apr; 15(5):569-72. PubMed ID: 24798711
    [No Abstract]   [Full Text] [Related]  

  • 28. Efavirenz intoxication due to a new CYP2B6 constellation.
    Anagnostopoulos A; Rotger M; Aouri M; Kuster SP; Telenti A; Décosterd LA; Günthard HF
    Antivir Ther; 2013; 18(5):739-43. PubMed ID: 23640958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic control of HIV disease.
    Theodorou I; Capoulade C; Combadiere C; Debre P
    Trends Microbiol; 2003 Aug; 11(8):392-7. PubMed ID: 12915097
    [No Abstract]   [Full Text] [Related]  

  • 30. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
    J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.
    Martín AS; Gómez AI; García-Berrocal B; Figueroa SC; Sánchez MC; Calvo Hernández MV; Gonzalez-Buitrago JM; Valverde Merino MP; Tovar CB; Martín AF; Isidoro-García M
    Pharmacogenomics; 2014 May; 15(7):997-1006. PubMed ID: 24956253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of anti-HIV drugs.
    Telenti A; Zanger UM
    Annu Rev Pharmacol Toxicol; 2008; 48():227-56. PubMed ID: 17883329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human genetic variability and HIV treatment response.
    Haas DW
    Curr HIV/AIDS Rep; 2006 Jul; 3(2):53-8. PubMed ID: 16608660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.
    Lubomirov R; Csajka C; Telenti A
    Pharmacogenomics; 2007 Jun; 8(6):623-33. PubMed ID: 17559351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.